BacAlt Biosciences: Financial Breakdown
Decoding financial health metrics of BacAlt Biosciences
Total Revenue₹23.2 Lakh111%Prev. FY
Total Expenses₹26.4 Lakh119%Prev. FY
Profit After Tax₹-3.3 Lakh-223%Prev. FY
Total Assets₹47.7 Lakh898%Prev. FY
Net Profit Margin-14.4%-53%Prev. FY
FAQs on Financials of BacAlt Biosciences
No. In FY25, BacAlt Biosciences reported a net loss of ₹3.3 Lakh, so it was not profitable.
BacAlt Biosciences's revenue grew 111.0% year-on-year, from ₹11.0 Lakh in FY24 to ₹23.2 Lakh in FY25.
BacAlt Biosciences's estimated EBITDA for FY25 was ₹-2.9 Lakh, derived from its profit before tax, finance costs, and depreciation & amortisation.
In FY25, BacAlt Biosciences posted revenue of ₹23.2 Lakh (up 111.0% YoY) and a net loss of ₹3.3 Lakh. Explore the full financials of BacAlt Biosciences here...
Disclaimer
Inc42 Datalabs consolidates intelligence from public records, statutory filings, proprietary research, and vetted third‑party datasets. All information is provided as is—please run your own checks before acting on it. Inc42 Datalabs bears no responsibility for decisions or outcomes based on this data.
Quick Links